{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:24:30Z","timestamp":1787009070112,"version":"build-2736575974"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T00:00:00Z","timestamp":1589932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Italian Department of Health"},{"name":"Ministero della Salute, Commissione per la vigilanza sul doping e sulla tutela sanitaria delle attivit\u00e0 sportive","award":["#2017_3"],"award-info":[{"award-number":["#2017_3"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This article presents newly developed screening and confirmation analytical procedures to detect the misuse of nine prolyl-hydroxylase inhibitors of the hypoxia-inducible factor: daprodustat, desidustat, FG2216, IOX2, IOX4, JNJ-42041935, molidustat, roxadustat and vadadustat, targeting either the parent drugs and\/or their main metabolite(s). For the sample pretreatment, different extraction protocols and technologies were evaluated. The instrumental analysis was performed by ultra-high-performance liquid chromatography coupled to either high- or low-resolution mass spectrometry. The chromatographic separation was performed on a C18 column, employing water and acetonitrile, both containing 0.1% formic acid, as mobile phase. Detection was achieved using as analyzer either a triple quadrupole or an Orbitrap, with positive and negative electrospray ionization and different acquisition modes. Validation of the procedures was performed according to the ISO 17025 and World Anti-Doping Agency guidelines. The methods do not show any significant interference at the retention times of the analytes of interest. The extraction efficiency was estimated to be greater than 75% for all analytes and the matrix effect smaller than 35%. Detection capability was determined in the range of 0.25\u20132.0 for the screening procedure and in the range of 0.5\u20132.0\u00a0ng\/mL for the confirmation procedure, that is, in a range of concentration small enough to reveal the abuse of the compounds considered, in case they are used as performance-enhancing agents. The repeatability of the relative retention times (CV%\u00a0&amp;lt;\u00a00.5) and of the relative abundances of the selected ion transitions, considered only in the case of triple quadrupole (CV%\u00a0&amp;lt;\u00a015), was confirmed to be fit for purpose to ensure the unambiguous identification of all the target analytes in human urine. The applicability of the newly developed methods was verified by the analysis of urine samples containing molidustat, roxadustat or daprodustat. The developed procedures enabled to detect the compounds under investigation and their main metabolites.<\/jats:p>","DOI":"10.1093\/jat\/bkaa055","type":"journal-article","created":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T15:15:43Z","timestamp":1589814943000},"page":"184-194","source":"Crossref","is-referenced-by-count":28,"title":["UPLC\u2013MS-Based Procedures to Detect Prolyl-Hydroxylase Inhibitors of HIF in Urine"],"prefix":"10.1093","volume":"45","author":[{"given":"Monica","family":"Mazzarino","sequence":"first","affiliation":[{"name":"Laboratorio Antidoping, Federazione Medico Sportiva Italiana, Largo Giulio Onesti, 1, Rome 00197, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Perretti","sequence":"additional","affiliation":[{"name":"Laboratorio Antidoping, Federazione Medico Sportiva Italiana, Largo Giulio Onesti, 1, Rome 00197, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlotta","family":"Stacchini","sequence":"additional","affiliation":[{"name":"Laboratorio Antidoping, Federazione Medico Sportiva Italiana, Largo Giulio Onesti, 1, Rome 00197, Italy"},{"name":"Dipartimento di Chimica e Tecnologia del Farmaco, \u2018Sapienza\u2019 Universit\u00e0 di Roma, Piazzale Aldo Moro 5, Rome 11085, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Comunit\u00e0","sequence":"additional","affiliation":[{"name":"Laboratorio Antidoping, Federazione Medico Sportiva Italiana, Largo Giulio Onesti, 1, Rome 00197, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"de la Torre","sequence":"additional","affiliation":[{"name":"Laboratorio Antidoping, Federazione Medico Sportiva Italiana, Largo Giulio Onesti, 1, Rome 00197, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Botr\u00e8","sequence":"additional","affiliation":[{"name":"Laboratorio Antidoping, Federazione Medico Sportiva Italiana, Largo Giulio Onesti, 1, Rome 00197, Italy"},{"name":"Dipartimento di Medicina Sperimentale, \u201cSapienza\u201d Universit\u00e0 di Roma, Viale Regina Elena, 324, Rome 00161, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,5,20]]},"reference":[{"key":"2021021309381473600_ref1","doi-asserted-by":"crossref","first-page":"9361","DOI":"10.1128\/MCB.23.24.9361-9374.2003","article-title":"Differential roles of hypoxia-inducible factor 1\u03b1 (HIF-1\u03b1) and HIF-2\u03b1 in hypoxic gene regulation","volume":"23","author":"Hu","year":"2003","journal-title":"Molecular and Cellular Biology"},{"key":"2021021309381473600_ref2","doi-asserted-by":"crossref","first-page":"7520","DOI":"10.1074\/jbc.M211298200","article-title":"Cooperative interaction of hypoxia-inducible factor-2\u03b1 (HIF-2\u03b1) and Ets-1 in the transcriptional activation of vascular endothelial growth factor receptor-2 (Flk-1)","volume":"278","author":"Elvert","year":"2003","journal-title":"The Journal of Biological Chemistry"},{"key":"2021021309381473600_ref3","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.yexcr.2017.03.041","article-title":"A compendium of proteins that interact with HIF-1\u03b1","volume":"356","author":"Semenza","year":"2017","journal-title":"Experimental Cell Research"},{"key":"2021021309381473600_ref4","doi-asserted-by":"crossref","first-page":"20661","DOI":"10.1074\/jbc.M116.749291","article-title":"Tuning the transcriptional response to hypoxia by inhibiting hypoxia-inducible factor (HIF) Prolyl and Asparaginyl hydroxylases","volume":"291","author":"Chan","year":"2016","journal-title":"The Journal of Biological Chemistry"},{"key":"2021021309381473600_ref5","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1126\/science.1073440","article-title":"Structure of an HIF-1alpha -pVHL complex: Hydroxyproline recognition in signaling","volume":"296","author":"Min","year":"2002","journal-title":"Science"},{"key":"2021021309381473600_ref6","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1517\/13543784.2011.566861","article-title":"HIF prolyl hydroxylase inhibitors for anemia","volume":"20","author":"Muchnik","year":"2011","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"2021021309381473600_ref7","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1517\/13543776.2010.510836","article-title":"Prolyl hydroxylase domain-containing protein inhibitors as stabilizers of hypoxia-inducible factor: Small molecule-based therapeutics for anemia","volume":"20","author":"Yan","year":"2010","journal-title":"Expert Opinion on Therapeutic Patents"},{"key":"2021021309381473600_ref8","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1182\/blood-2006-08-019083","article-title":"New agents that stimulate erythropoiesis","volume":"109","author":"Bunn","year":"2007","journal-title":"Blood"},{"key":"2021021309381473600_ref9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nrneph.2015.193","article-title":"HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond","volume":"12","author":"Maxwell","year":"2016","journal-title":"Nature Reviews. Nephrology"},{"key":"2021021309381473600_ref10","first-page":"51","article-title":"Hypoxia-inducible factor (HIF)-1 regulatory pathway and its potential for therapeutic intervention in malignancy and ischemia","volume":"80","author":"Ziello","year":"2007","journal-title":"The Yale Journal of Biology and Medicine"},{"key":"2021021309381473600_ref11","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/nrd4422","article-title":"Targeting hypoxia signaling for the treatment of ischaemic and inflammatory diseases","volume":"13","author":"Eltzschig","year":"2014","journal-title":"Nature Reviews. Drug Discovery"},{"key":"2021021309381473600_ref12","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.apsb.2015.05.007","article-title":"HIF-1\u03b1 pathway: Role, regulation and intervention for cancer therapy","volume":"5","author":"Masoud","year":"2015","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"2021021309381473600_ref13","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.pharmthera.2016.04.009","article-title":"Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer","volume":"164","author":"Wigerup","year":"2016","journal-title":"Pharmacology & Therapeutics"},{"key":"2021021309381473600_ref14","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1016\/S0960-894X(03)00539-0","article-title":"2-oxoglutarate analogue inhibitors of HIF prolyl hydroxylase","volume":"13","author":"Mole","year":"2003","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"2021021309381473600_ref15","doi-asserted-by":"crossref","first-page":"982","DOI":"10.2215\/CJN.06890615","article-title":"Oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) for the treatment of anemia in patients with CKD","volume":"11","author":"Provenzano","year":"2016","journal-title":"Clinical Journal of the American Society of Nephrology"},{"key":"2021021309381473600_ref16","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1053\/j.ajkd.2015.11.021","article-title":"A novel hypoxia-inducible factor-prolyl hydroxylase inhibitor (GSK1278863) for anemia in CKD: A 28-day, phase 2A randomized trial","volume":"67","author":"Brigandi","year":"2016","journal-title":"American Journal of Kidney Diseases"},{"key":"2021021309381473600_ref17","doi-asserted-by":"crossref","first-page":"e111838","DOI":"10.1371\/journal.pone.0111838","article-title":"Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects","volume":"9","author":"Flamme","year":"2014","journal-title":"PLoS One"},{"key":"2021021309381473600_ref18","volume-title":"The 2020 Prohibited List","author":"World Anti-Doping Agency","year":"2020"},{"key":"2021021309381473600_ref19","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/dta.390","article-title":"Hypoxia-inducible factor stabilizers and other small-molecule erythropoiesis-stimulating agents in current preventive doping analysis","volume":"4","author":"Beuck","year":"2012","journal-title":"Drug Testing and Analysis"},{"key":"2021021309381473600_ref20","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jpba.2014.05.020","article-title":"Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls","volume":"101","author":"Thevis","year":"2014","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"2021021309381473600_ref21","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/dta.365","article-title":"Development of liquid chromatography-tandem mass spectrometry-based analytical assays for the determination of HIF stabilizers in preventive doping research","volume":"3","author":"Beuck","year":"2011","journal-title":"Drug Testing and Analysis"},{"key":"2021021309381473600_ref22","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jpba.2016.01.029","article-title":"Detection by LC\u2013MS\/MS of HIF stabilizer FG-4592 used as a new doping agent: Investigation on a positive case","volume":"121","author":"Buisson","year":"2016","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"2021021309381473600_ref23","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jpba.2016.11.041","article-title":"Investigation of the metabolites of the HIF stabilizer FG-4592 (roxadustat) in five different in vitro models and in a human doping control sample using high resolution mass spectrometry","volume":"134","author":"Hansson","year":"2017","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"2021021309381473600_ref24","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1002\/dta.2202","article-title":"Implementation of the prolyl hydroxylase inhibitor Roxadustat (FG-4592) and its main metabolites into routine doping controls","volume":"9","author":"Eichner","year":"2017","journal-title":"Drug Testing and Analysis"},{"key":"2021021309381473600_ref25","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/dta.1870","article-title":"Mass spectrometric characterization of a prolyl hydroxylase inhibitor GSK1278863, its bishydroxylated metabolite, and its implementation into routine doping controls","volume":"8","author":"Thevis","year":"2016","journal-title":"Drug Testing and Analysis"},{"key":"2021021309381473600_ref26","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/dta.2011","article-title":"Mass spectrometric characterization of the hypoxia-inducible factor (HIF) stabilizer drug candidate BAY 85-3934 (molidustat) and its glucuronidated metabolite BAY-348, and their implementation into routine doping controls","volume":"9","author":"Dib","year":"2017","journal-title":"Drug Testing and Analysis"},{"key":"2021021309381473600_ref27","volume-title":"ISO\/IEC17025:2017","author":"International Organization for Standardization"},{"key":"2021021309381473600_ref28","volume-title":"International Standard for Laboratories","author":"World Anti-Doping Agency","year":"2019"},{"key":"2021021309381473600_ref29","volume-title":"Technical Documents","author":"World Anti-Doping Agency"},{"key":"2021021309381473600_ref30","volume-title":"Identification criteria for qualitative assays incorporating column chromatography and mass spectrometry, (WADA Technical Document TD 2015IDCR)","author":"World Anti-Doping Agency"},{"key":"2021021309381473600_ref31","volume-title":"Oasis Sample Extraction Protocols","author":"WATERS"},{"key":"2021021309381473600_ref32","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1002\/dta.2702","article-title":"Detection of 5\u03b1-reductase inhibitors by UPLC\u2013MS\/MS: Application to the definition of the excretion profile of dutasteride in urine","volume":"11","author":"Mazzarino","year":"2019","journal-title":"Drug Testing and Analysis"},{"key":"2021021309381473600_ref33","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s11419-015-0279-4","article-title":"Development and validation of a liquid chromatography-mass spectrometry procedure after solid phase extraction for detection of 19 doping peptides in human urine","volume":"33","author":"Mazzarino","year":"2015","journal-title":"Forensic Toxicology"},{"key":"2021021309381473600_ref34","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jpba.2015.08.007","article-title":"A multi-targeted liquid chromatography-mass spectrometry screening procedure for the detection in human urine of drugs non-prohibited in sport commonly used by the athletes","volume":"117","author":"Mazzarino","year":"2016","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"2021021309381473600_ref35","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s11419-016-0325-x","article-title":"Drug-drug interactions and masking effects in sport doping: Influence of miconazole administration on the urinary concentrations of endogenous anabolic steroids","volume":"34","author":"Palermo","year":"2016","journal-title":"Forensic Toxicology"},{"key":"2021021309381473600_ref36","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.4155\/bio-2016-0083","article-title":"Multianalyte LC\u2013MS-based methods in doping control: What are the implications for doping athletes?","volume":"8","author":"Botr\u00e8","year":"2016","journal-title":"Bioanalysis"}],"container-title":["Journal of Analytical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jat\/advance-article-pdf\/doi\/10.1093\/jat\/bkaa055\/33487363\/bkaa055.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jat\/article-pdf\/45\/2\/184\/36249899\/bkaa055.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jat\/article-pdf\/45\/2\/184\/36249899\/bkaa055.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,14]],"date-time":"2021-02-14T03:20:06Z","timestamp":1613272806000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jat\/article\/45\/2\/184\/5841139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,20]]},"references-count":36,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,5,20]]},"published-print":{"date-parts":[[2021,2,13]]}},"URL":"https:\/\/doi.org\/10.1093\/jat\/bkaa055","relation":{},"ISSN":["0146-4760","1945-2403"],"issn-type":[{"value":"0146-4760","type":"print"},{"value":"1945-2403","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,3,1]]},"published":{"date-parts":[[2020,5,20]]}}}